- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Jazz Pharmaceuticals PLC(JAZZ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for JAZZ
11/17/2026: JAZZ (5-star) is a STRONG-BUY. BUY for 5 days. Simulated Profits (-3.03%). Updated daily EoD!
Jazz Pharmaceuticals PLC is a global biopharmaceutical company specializing in neuroscience and oncology therapeutics. The company benefits from established commercial franchises, notably sleep disorder treatments like Xywav and epilepsy medications like Epidiolex, which support healthy operating margins. Its primary growth strategy centers on label expansions, pipeline advancements, and previous strategic acquisitions. However, the company faces key risks from generic competition, patent expirations, and integration debt leverage. The stock is best suited for growth-oriented healthcare investors who monitor clinical trial readouts, patent litigation milestones, and debt reduction progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Moderate top-line growth is counterbalanced by heavy reliance on key specialty franchises and integration execution. |
| Momentum investor | Strong fit while signal remains positive | Momentum fit is conditional on positive clinical data readouts and bullish near-term technical breakout signals. |
| Value investor | Mixed fit | The stock trades at valuation multiples that require careful assessment against generic erosion risks and debt levels. |
| Dividend investor | Weak fit | Jazz Pharmaceuticals does not pay a regular dividend, prioritizing capital allocation toward growth and debt paydown. |
| Low-risk investor | Weak fit | Biopharmaceutical regulatory hurdles, litigation risks, and clinical trial dependencies create notable volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock reacts sharply to clinical trial results, regulatory decisions, and quarterly product sales updates. |
| Valuation risk | Medium | Valuation depends on sustainable long-term cash flows from core products amidst upcoming patent expirations. |
| Competition risk (generic and alternative drug substitution) | High | Generic challengers and new alternative medications threaten the market share of legacy products like Xyrem. |
| Business quality | Medium / high | Jazz features established specialized franchises with robust operating margins, though portfolio diversification remains ongoing. |
| Dividend income | Low / none | Income-focused investors receive no dividend yield as all earnings are reinvested internally. |
| Execution risk | Medium / high | Successful clinical development, regulatory approvals, and pipeline commercialization are vital for future growth. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.39B USD | Price to earnings Ratio 70.94 | 1Y Target Price 297.5 |
Price to earnings Ratio 70.94 | 1Y Target Price 297.5 | ||
Volume (30-day avg) 807.0K shares | Beta 0.37 | 52 Weeks Range 156.95 - 266.38 | Updated Date 11/17/2026 |
52 Weeks Range 156.95 - 266.38 | Updated Date 11/17/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.38 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 62.3%
- Active BUY / eligible
- 66 / 106
- 30-Day BUY Count Change
- +23
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.6%
- Active BUY / eligible
- 17 / 39
- 30-Day BUY Count Change
- +10
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 83.55% | Avg. Invested days 70 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Neuroscience portfolio | Revenues from key sleep and neurology medications including Xywav, Xyrem, and Epidiolex. | This is the primary earnings engine, though it faces ongoing generic and transition pressures. |
| Oncology portfolio | Sales from targeted cancer therapeutics such as Vyxeos, Zepzelca, and Rylaze. | Provides vital product diversification into specialized cancer treatments with strong growth potential. |
| Geographic Operations | Commercial sales generated primarily across the United States, alongside expanding European and international markets. | US market dominance drives the bulk of financial results, with international regions offering supplementary expansion. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 70.94 | Forward PE 10.33 | Enterprise Value 18.29B | Price to Sales(TTM) 3.26 |
Enterprise Value 18.29B | Price to Sales(TTM) 3.26 | ||
Enterprise Value to Revenue 3.88 | Enterprise Value to EBITDA 15.96 | Shares Outstanding 64.19M | Shares Floating 62.25M |
Shares Outstanding 64.19M | Shares Floating 62.25M | ||
Percent Insiders 3.41 | Percent Institutions 106.06 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

